Management of gout and hyperuricemia: Multidisciplinary consensus in Taiwan-Reference-Cited by-同舟云学术

Management of gout and hyperuricemia: Multidisciplinary consensus in Taiwan

Published:2018-01-24 Issue:4 Volume:21 Page:772-787
ISSN:1756-1841
Container-title:International Journal of Rheumatic Diseases
language:en
Short-container-title:Int J Rheum Dis

Author:

Yu Kuang-Hui¹^ORCID,Chen Der-Yuan²³⁴,Chen Jiunn-Horng⁵⁶,Chen Shih-Yang⁷,Chen Shyh-Ming⁸,Cheng Tien-Tsai⁹,Hsieh Song-Chou¹⁰,Hsieh Tsu-Yi¹¹¹²,Hsu Pai-Feng²¹³,Kuo Chang-Fu¹,Kuo Mei-Chuan¹⁴¹⁵,Lam Hing-Chung¹⁶,Lee I-Te²¹⁷,Liang Toong-Hua¹⁸,Lin Hsiao-Yi²¹⁹,Lin Shih-Chang²⁰²¹,Tsai Wen-Pin²²,Tsay Gregory J.⁵⁶,Wei James Cheng-Chung²³²⁴²⁵,Yang Chung-Han¹²⁶,Tsai Wen-Chan²⁷

Affiliation:

1. Division of Rheumatology, Allergy, and Immunology; Chang Gung Memorial Hospital; Chang Gung University; Taipei Taiwan

2. Faculty of Medicine; National Yang-Ming University; Taipei Taiwan

3. Department of Internal Medicine; Taichung Veterans General Hospital; Taichung Taiwan

4. Ph.D. Program in Translational Medicine; Rong Hsing Research Center for Translational Medicine; National Chung Hsing University; Taichung Taiwan

5. Division of Immunology and Rheumatology; Department of Internal Medicine; China Medical University Hospital; Taichung Taiwan

6. School of Medicine; College of Medicine; China Medical University; Taichung Taiwan

7. Center of Gout; Country Hospital; Taipei Taiwan

8. Division of Cardiology; Department of Internal Medicine; Kaohsiung Chang Gung Memorial Hospital; Chang Gung University; Kaohsiung Taiwan

9. Division of Rheumatology, Allergy and Immunology; Department of Internal Medicine; Kaohsiung Chang Gung Memorial Hospital; Chang Gung University; Kaohsiung Taiwan

10. Division of Rheumatology, Immunology and Allergy; Department of Internal Medicine; National Taiwan University Hospital; Hsinchu Taiwan

11. Division of Allergy, Immunology, and Rheumatology; Department of Internal Medicine; Taichung Veterans General Hospital; Taichung Taiwan

12. Ph.D. Program of Business; Institute of Business; Feng-Chia University; Taichung Taiwan

13. Department of Healthcare and Services Center; Taipei Veterans General Hospital; Taipei Taiwan

14. Division of Nephrology; Kaohsiung Medical University Hospital; Kaohsiung Taiwan

15. Faculty of Renal Care; Kaohsiung Medical University; Kaohsiung Taiwan

16. Division of Endocrinology and Metabolism; Department of Internal Medicine; E-Da Hospital/I-Shou University; Kaohsiung Taiwan

17. Division of Endocrinology and Metabolism; Department of Internal Medicine; Taichung Veterans General Hospital; Taichung Taiwan

18. Rheumatology Section; Renai Branch; Taipei City Hospital; Taipei Taiwan

19. Division of Allergy, Immunology and Rheumatology; Department of Medicine; Cheng Hsin General Hospital; Taipei Taiwan

20. Division of Rheumatology and Immunology; Cathay General Hospital; Taipei Taiwan

21. Department of Medicine; College of Medicine; Fu-Jen Catholic University; New Taipei Taiwan

22. Department of Immunology and Rheumatology; Hsinchu MacKay Memorial Hospital; Hsinchu Taiwan

23. Division of Allergy, Immunology and Rheumatology; Chung Shan Medical University Hospital; Taichung Taiwan

24. Institute of Medicine; Chung Shan Medical University; Taichung Taiwan

25. Graduate Institute of Integrated Medicine; China Medical University; Taichung Taiwan

26. Department of Internal Medicine; Landseed Hospital; Taoyuan Taiwan

27. Department of Allergy, Immunology, and Rheumatology; Kaohsiung Medical University Hospital; Kaohsiung Taiwan

Funder

Astellas Pharma

Publisher

Wiley

Subject

Rheumatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/1756-185X.13266/fullpdf

Reference64 articles.

1. Global epidemiology of gout: prevalence, incidence and risk factors;Kuo;Nat Rev Rheumatol,2015

2. Epidemiology and management of gout in Taiwan: a nationwide population study;Kuo;Arthritis Res Ther,2015

3. Trends in hyperuricemia and gout prevalence: Nutrition and Health Survey in Taiwan from 1993-1996 to 2005-2008;Chuang;Asia Pac J Clin Nutr,2011

4. Familial aggregation of gout and relative genetic and environmental contributions: a nationwide population study in Taiwan;Kuo;Ann Rheum Dis,2015

5. Howick J Chalmers I Glasziou P et al 2011 OCEBM Levels of Evidence Working Group. “The Oxford 2011 Levels of Evidence” http://www.cebm.net/index.aspx?o=5653

Cited by 91 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comment on serum urate‐lowering efficacy and safety of Tigulixostat in gout patients with hyperuricemia: A randomized, double‐blind, placebo‐controlled, dose‐finding trial;International Journal of Rheumatic Diseases;2024-01

2. Restoring skeletal muscle mass as an independent determinant of liver fat deposition improvement in MAFLD;Skeletal Muscle;2023-12-19

3. A dose-escalation study of HP501, a highly selective URAT1 inhibitor, in male Chinese patients with hyperuricemia;Scientific Reports;2023-12-14

4. Response to febuxostat according to clinical subtypes of hyperuricemia: a prospective cohort study in primary gout;Arthritis Research & Therapy;2023-12-11

5. Peptide NCTX15 derived from spider toxin gland effectively relieves hyperuricemia in mice;Biochemical and Biophysical Research Communications;2023-12